AstraZeneca invests $3.5 billion in US as cancer drugs boost sales

AstraZeneca Plc raised its full-year forecast due to strong demand for its blockbuster cancer drugs and said it would invest $3.5 billion in its U.S. business by the end of 2026.

Earnings per share (excluding some items) are now expected to increase by a high-teens percentage, up from a previously forecast mid-teens percentage, the company said Tuesday. Top-selling cancer drug Tagrisso was a key driver as sales performed better than expected, while sales of newcomer Enhertu also exceeded expectations.